TY - JOUR
T1 - High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling
AU - Romano, A.
AU - Parrinello, N. L.
AU - Simeon, V.
AU - Puglisi, F.
AU - La Cava, P.
AU - Bellofiore, C.
AU - Giallongo, C.
AU - Camiolo, G.
AU - D’Auria, F.
AU - Grieco, V.
AU - Larocca, F.
AU - Barbato, A.
AU - Cambria, D.
AU - La Spina, E.
AU - Tibullo, D.
AU - Palumbo, G. A.
AU - Conticello, C.
AU - Musto, P.
AU - Di Raimondo, F.
N1 - Funding Information:
This work was partially supported by AIRC (Associazione Italiana per la Ricerca sul Cancro, FDR, IG22131), Collegio Ghislieri (AR), SIES (AR), International Myeloma Foundation (AR) and by “Piano per la ricerca 2016– 2018 – Linea di intervento 2 “Dotazione ordinaria CHIRMED”, University of Catania, Italy.
Publisher Copyright:
© 2020, The Author(s).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - To understand neutrophil impairment in the progression from MGUS through active MM, we investigated the function of mature, high-density neutrophils (HDNs), isolated from peripheral blood. In 7 MM, 3 MGUS and 3 healthy subjects by gene expression profile, we identified a total of 551 upregulated and 343 downregulated genes in MM-HDN, involved in chemokine signaling pathway and FC-gamma receptor mediated phagocytosis conveying in the activation of STAT proteins. In a series of 60 newly diagnosed MM and 30 MGUS patients, by flow-cytometry we found that HDN from MM, and to a lesser extend MGUS, had an up-regulation of the inducible FcγRI (also known as CD64) and a down-regulation of the constitutive FcγRIIIa (also known as CD16) together with a reduced phagocytic activity and oxidative burst, associated to increased immune-suppression that could be reverted by arginase inhibitors in co-culture with lymphocytes. In 43 consecutive newly-diagnosed MM patients, who received first-line treatment based on bortezomib, thalidomide and dexamethasone, high CD64 could identify at diagnosis patients with inferior median overall survival (39.5 versus 86.7 months, p = 0.04). Thus, HDNs are significantly different among healthy, MGUS and MM subjects. In both MGUS and MM neutrophils may play a role in supporting both the increased susceptibility to infection and the immunological dysfunction that leads to tumor progression.
AB - To understand neutrophil impairment in the progression from MGUS through active MM, we investigated the function of mature, high-density neutrophils (HDNs), isolated from peripheral blood. In 7 MM, 3 MGUS and 3 healthy subjects by gene expression profile, we identified a total of 551 upregulated and 343 downregulated genes in MM-HDN, involved in chemokine signaling pathway and FC-gamma receptor mediated phagocytosis conveying in the activation of STAT proteins. In a series of 60 newly diagnosed MM and 30 MGUS patients, by flow-cytometry we found that HDN from MM, and to a lesser extend MGUS, had an up-regulation of the inducible FcγRI (also known as CD64) and a down-regulation of the constitutive FcγRIIIa (also known as CD16) together with a reduced phagocytic activity and oxidative burst, associated to increased immune-suppression that could be reverted by arginase inhibitors in co-culture with lymphocytes. In 43 consecutive newly-diagnosed MM patients, who received first-line treatment based on bortezomib, thalidomide and dexamethasone, high CD64 could identify at diagnosis patients with inferior median overall survival (39.5 versus 86.7 months, p = 0.04). Thus, HDNs are significantly different among healthy, MGUS and MM subjects. In both MGUS and MM neutrophils may play a role in supporting both the increased susceptibility to infection and the immunological dysfunction that leads to tumor progression.
UR - http://www.scopus.com/inward/record.url?scp=85079070830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079070830&partnerID=8YFLogxK
U2 - 10.1038/s41598-020-58859-x
DO - 10.1038/s41598-020-58859-x
M3 - Article
C2 - 32029833
AN - SCOPUS:85079070830
VL - 10
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 1983
ER -